GH RESEARCH PLC

GHRSNASDAQ

🏆 #2157 by market capUS Equity

$83.51▲ $5.67 (+6.79%)

Simulated price

🔔

Track GHRS

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 6.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1.61B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for GHRS.

Trading Snapshot

Day Range: $82.75 – $84.24
52-Week Range: $12.04 – $31.44
Volume: $3.27B
Avg Volume: $3.42B
Shares Outstanding: 68.6M
Next Earnings: Nov 10, 2026

Fundamentals Snapshot

Annual Revenue: $103M
Last Q Revenue: $26M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.99
Dividend Yield: —

Why Investors Own GHRS

✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GH RESEARCH PLC

GHRS

Financial Trends

Revenue (TTM)

$103M▼ −2.8% YoY

Gross Margin (TTM)

64.9%▲ +3.3% YoY

Operating Income (TTM)

$12M▼ −2.8% YoY

Free Cash Flow (TTM)

$23M▼ −2.8% YoY

StockOtter · stockotter.space

About GH RESEARCH PLC

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

🦦